April 1st 2024
The sBLA for once-monthly maintenance IV dosing of lecanemab is complete but a rolling application for a weekly subQ option has been set back, said Eisai.
Cardiometabolic Diseases and Dementia Risk Show Dose-dependent Relationship in Large Twin Study
January 13th 2023For each cardiometabolic disease, the risk of all-cause dementia rose by 42%; the risk rose 26% for Alzheimer disease and 64% for vascular dementia. Temporal onset and genetics play key roles.